Ceva Completes Deal to Acquire Portfolio of Merial Swine and Cattle Vaccines and Nonsteroidal Anti-inflammatories from Boehringer Ingelheim

Food and Healthcare Press Releases Friday January 20, 2017 10:34
LIBOURNE, France--20 Jan--PRNewswire/InfoQuest

Ceva Sante Animale today completed the acquisition of a diversified portfolio of products, including swine and cattle vaccines and multi-species nonsteroidal anti-inflammatories from Boehringer Ingelheim following its acquisition of Merial Animal Health.

All the products will be immediately available through local Ceva companies or its distributors, with no interruption of supply.
Ceva has been consistently one of the fastest growing top 10 veterinary businesses in the last decade, investing heavily in the development of vaccines, as part of its global preventative health strategy.
Commenting on the deal, Ceva Chairman & CEO Dr. Marc Prikazsky said:

"We are delighted to acquire this range of products and strong pipeline of R&D assets.   The knowhow behind these products dates from Pasteur, Rhone-Merieux, Merial and now as Ceva we are conscious that we have a responsibility to maintain this strong veterinary scientific tradition.   Our customers can be assured that we will continue to invest to develop the products of both today and tomorrow."

ABOUT CEVA SANTE ANIMALE

Ceva Sante Animale was founded in 1999 and is a global veterinary health company, focused on research, development, production and marketing of pharmaceutical products and vaccines for companion animals, livestock, swine and poultry. Its headquarters are in Libourne (Gironde). Ceva Chairman and CEO is Marc Prikazsky.

Website: http://www.ceva.com
PRESS CONTACT
Martin Mitchell
Communication Director
+33-05-57-55-40-80
martin.mitchell@ceva.com
Company: Davidson Ryan Dore
Lawrence Dore
Lawrence.dore@drdpartnership.com
Phone: +44(0)207-520-9218
Source: Ceva Sante Animale

Latest Press Release

2017 Cigna 360 degree Well-being Survey - Positive Aspects of Working Overseas Often Overshadowed by Health and Financial concerns

- Globally mobile individuals perceive themselves as worse-off than individuals who reside in their home country and have not taken overseas assignments - Family time and support are major concerns - Many worry about the financial consequence and...

Pan Rajdhevee Group Unveils Pan Acne Formula Three Lotion, the Worlds First Acne Solution Innovation, with the #ShockAcneIn3Days Campaign

Pan Rajdhevee Group, Thailand's leading cosmeceutical brand, pushed forth in continuously developing skincare innovations and introduced "Pan Acne Formula Three Lotion," the ultimate acne solution without relying on any medicine. The solution targets...

ViiV Healthcare Announces Superior Efficacy of Dolutegravir Versus Lopinavir/Ritonavir in Second-line HIV Treatment in Resource-limited Settings

DAWNING study modified to allow patients the opportunity to receive dolutegravir-based regimens ViiV Healthcare, the global specialist HIV company, majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive...

Unique concept of MDx, Seegene Random Access System, announced at AACC 2017

Seegene Inc. (096530.KQ), the world's leading developer of multiplex molecular diagnostics technologies and assays, is to present its unique Seegene Random Access System (the "System") at the 69th AACC Annual Clinical Lab Expo in San Diego, CA, from July...

U.S. FDA Determines Celliant(R) Responsive Textile Products Meet Criteria as Medical Devices and General Wellness Products

- Celliant-engineered products clinically proven to promote increased localized blood flow - FDA determination to usher in new era of performance fabrics, responsive textiles Hologenix, LLC, maker of Celliant , the world's most advanced, clinically...

Related Topics